Anti-NMDA and Anti-AMPA Receptor Antibodies in Central Disorders: Preclinical Approaches to Assess Their Pathological Role and Translatability to Clinic.
Guendalina OliveroAlessandra RoggeriAnna PittalugaPublished in: International journal of molecular sciences (2023)
Autoantibodies against NMDA and AMPA receptors have been identified in the central nervous system of patients suffering from brain disorders characterized by neurological and psychiatric symptoms. It has been demonstrated that these autoantibodies can affect the functions and/or the expression of the targeted receptors, altering synaptic communication. The importance to clarify, in preclinical models, the molecular mechanisms involved in the autoantibody-mediated effects has emerged in order to understand their pathogenic role in central disorders, but also to propose new therapeutic approaches for preventing the deleterious central consequences. In this review, we describe some of the available preclinical literature concerning the impact of antibodies recognizing NMDA and AMPA receptors in neurons. This review discusses the cellular events that would support the detrimental roles of the autoantibodies, also illustrating some contrasting findings that in our opinion deserve attention and further investigations before translating the preclinical observations to clinic.
Keyphrases
- systemic lupus erythematosus
- cell therapy
- end stage renal disease
- primary care
- ejection fraction
- newly diagnosed
- systematic review
- poor prognosis
- mental health
- prognostic factors
- peritoneal dialysis
- spinal cord
- binding protein
- white matter
- depressive symptoms
- patient reported outcomes
- cancer therapy
- spinal cord injury
- blood brain barrier
- patient reported
- subarachnoid hemorrhage